New Copper and Rhenium Radiopharmaceuticals

新型铜铼放射性药物

• 批准号: DP0452845
• 负责人: Prof Paul Donnelly
• 金额: $ 16.69万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-07-30 至 2007-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0452845
• 关键词: New; Copper; Rhenium; Radiopharmaceuticals

The aims of this project are to provide new metal-based radiopharmaceuticals for the treatment of cancer, and the imaging of cancer and other conditions through the design and engineering of new coordination complexes of rhenium and copper. Various strategies will be used to selectively and specifically target these metal complexes to the desired areas in vivo for non-invasive imaging and therapeutic applications. The most promising candidates will be tested in the appropriate cells.

该项目的目的是通过设计和制造新的铜和铜的配位络合物，提供新的金属基放射性药物，用于治疗癌症，以及癌症和其他疾病的成像。将使用各种策略来选择性地和特异性地将这些金属络合物靶向到体内所需的区域，用于非侵入性成像和治疗应用。最有希望的候选人将在适当的牢房接受测试。